5-Amino-1MQ: Research & Studies

Research Overview#

Evidence Level: Preclinical Only -- All published research on 5-Amino-1MQ consists of cell culture (in vitro) and animal (in vivo) studies. No human clinical trials have been published or registered. All conclusions below pertain to mouse and cell models, not humans.

5-Amino-1MQ research centers on three key studies from overlapping research groups at the University of Texas Medical Branch (UTMB) and affiliated institutions. The compound was first characterized in 2018 as a selective NNMT inhibitor with anti-obesity properties, followed by studies on gut microbiome effects (2022) and muscle function in aging (2024).

The consistency of research groups across all studies is notable -- while this provides a coherent research narrative, it also means the findings have not been independently replicated by external laboratories.

Key Studies#

Obesity and Metabolic Effects (2018)#

The foundational study by Neelakantan et al. (PMID: 29155147) established 5-Amino-1MQ as a potent and selective NNMT inhibitor. Key design elements:

• In vitro: Tested in 3T3-L1 adipocytes at concentrations of 1-60 microM
• In vivo: Mice fed high-fat diet for 16 weeks to induce obesity, then randomized to treatment (20 mg/kg/injection subcutaneous, 3 injections daily totaling ~34 mg/kg/day) or control for 11 days
• Results: Significant reductions in body weight, white adipose tissue mass, and adipocyte size; 1.2-1.6 fold increase in intracellular NAD+; suppressed lipogenesis; no change in food intake
• Selectivity: Did not inhibit related SAM-dependent methyltransferases (GNMT, HNMT) or NAD+ salvage enzymes (NAMPT, NMNAT)

This study established the mechanism of action and provided the first in vivo evidence of therapeutic potential.

Microbiome and Combination Therapy (2022)#

Neelakantan et al. (PMID: 35013352) extended the obesity work by combining NNMT inhibition with dietary intervention:

• The combination of 5-Amino-1MQ and reduced-calorie diet rapidly normalized body composition in obese mice -- faster than diet alone
• Treated animals developed a unique gut microbiome distinct from both obese and continuously lean controls
• Increased abundance of Lactobacillus species (associated with weight loss)
• Proposed mechanistic link: NNMT inhibition increases nicotinamide availability, which Lactobacillus species require for growth

Muscle Function in Aging (2024)#

Dimet-Wiley et al. (PMID: 38969654) explored sarcopenia-relevant applications:

• Aged mice were divided into four groups: sedentary control, NNMTi only, exercise only, NNMTi + exercise
• NNMTi alone produced greater grip strength improvements (40%) than exercise alone (20%)
• The combination was additive, achieving 60% improvement
• Proteomic and metabolomic analyses revealed that NNMTi activates molecular pathways distinct from those engaged by exercise
• Suggests NNMTi could complement exercise for maintaining muscle function during aging

Evidence Quality Assessment#

The evidence for 5-Amino-1MQ is rated as low:

Strengths:

• Published in reputable peer-reviewed journals (Biochemical Pharmacology, Scientific Reports)
• Clear mechanistic rationale linking NNMT inhibition to NAD+ increases
• Consistent results across multiple animal studies
• High target selectivity reduces off-target concern in preclinical models
• No adverse effects observed in animal studies

Critical Limitations:

• No human data whatsoever -- the complete absence of clinical trials is the most important limitation
• All studies from overlapping research groups at UTMB and affiliates
• Small animal group sizes
• Short treatment durations (11 days in obesity study)
• Subcutaneous injection route in animals, while human products are often oral capsules -- oral bioavailability is not established
• Mouse metabolism differs substantially from human metabolism, particularly in NAD+ dynamics
• The compound is widely sold despite having zero human efficacy or safety data

Research Gaps#

The following represent critical unknowns for 5-Amino-1MQ:

1. Human pharmacology -- PK/PD, bioavailability, half-life, and dose-response in humans are completely unknown
2. Human safety -- no toxicology, reproductive toxicology, or carcinogenicity data in humans
3. Oral bioavailability -- despite oral capsule products being sold, oral absorption has not been characterized in published studies (animal studies used subcutaneous injection)
4. Long-term NNMT inhibition -- chronic effects on methylation balance, epigenetics, and metabolic homeostasis are unstudied
5. Cancer risk -- NNMT has been implicated as both tumor-promoting and tumor-suppressive depending on cancer type; long-term inhibition effects are unknown
6. NAD+ precursor comparisons -- no studies comparing 5-Amino-1MQ to NMN, NR, or other NAD+ boosters
7. Human muscle effects -- whether the dramatic aged mouse muscle improvements translate to humans is unknown
8. Drug interactions -- potential interactions with medications affecting methylation or NAD+ pathways have not been studied